The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer

Human Pathology

Volumn 43, Issue 7, 2012, Pages 1044-1050

  Zhang, Jingdong ^a   Gill, Anthony J M ^b   Issacs, Joseph D ^b   Atmore, Bryn ^b   Johns, Amber ^c   Delbridge, Leigh W ^b   Lai, Raymond ^a   McMullen, Todd P W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

catenin; Cyclin D1; GSK 3 ; Metastases; Papillary thyroid cancer

Indexed keywords

BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; WNT PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; UPREGULATION;

BETA CATENIN; CARCINOMA, PAPILLARY; CYCLIN D1; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHOSPHORYLATION; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WNT SIGNALING PATHWAY;

EID: 84862536126     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.08.013     Document Type: Article

References (28)

1. Pai SI, Tufano RP. Reoperation for recurrent/persistent well-differentiated thyroid cancer. Otolaryngol Clin North Am 2010;43:353-63.
2. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006;106:524-31.
3. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 1996;18:127-32.
4. Machens A, Hinze R, Thomusch O, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26:22-8.
5. Coburn M, Teates D, Wanebo JH. Recurrent thyroid cancer. Role of surgery versus radioactive iodine [I131]. Ann Surg 1994;219:587-93.
6. Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol 2009;99:186-8.
7. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association [ATA] Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009;19:1167-214.
8. Udelsman R. Treatment of persistent or recurrent papillary carcinoma of the thyroid-the good, the bad, and the unknown. J Clin Endocrinol Metab 2010;95:2061-3.
9. Machens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery 2009;145:176-81.
10. Dralle H, Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab 2008;22:971-87.
11. Melck A, Masoudi H, Griffith OL, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol 2007;14:3403-11.
12. Takahashi-Yanaga F, Sasaguri T. GSK-3β regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008;20:581-9.
13. Jung CK, Kang YG, Bae JS, et al. Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 2010;23:1201-8.
14. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
15. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008;20:581-9.
16. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002;1:226-31.
17. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
18. Kim L, Kimmel AR. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 2000;10:508-14.
19. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 2002;84:203-29.
20. Lee SH, Lee JK, Jin SM, et al. Expression of cell-cycle regulators [cyclin D1, cyclin E, p27kip1, p57kip2] in papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2010;142:332-7.
21. Cho YJ, Kim JH, Yoon J, et al. Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer. BMC Gastroenterol 2010;10:91-9.
22. Chung R, Peters AC, Armanious H, et al. Biological and clinical significance of GSK-3β in mantle cell lymphoma - an immunohisto-chemical study. Int J Clin Exp Pathol 2010;3:244-53.
23. Wang J, Wang X, Gong W, et al. Increased expression of beta-catenin, phosphorylated glycogen synthase kinase 3β, cyclin D1, and c-myc in laterally spreading colorectal tumors. J Histochem Cytochem 2009;57:363-71.
24. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47.
25. Kato MA, Fahey III TJ. Molecular markers in thyroid cancer diagnostics. Surg Clin North Am 2009;89:1139-55.
26. Chiu CG, Strugnell SS, Griffith OL, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-81.
27. Liang H, Zhong Y, Luo Z, et al. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. Int J Biol Markers 2010;25:38-45.
28. Tian X, Cong M, Zhou W, et al. Relationship between protein expression of VEGF-C. MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res 2008;36:699-703.